24.219.5010    QUALIFIED TREATMENT PROGRAM

(1) Qualified treatment programs include those addiction treatment programs where candidates may obtain supervised work experience based on nationally recognized patient placement criteria. Criteria for these treatment settings may include settings that provide the basis for a continuum of care for patients with addictions and settings that include any level of care as defined by American Society of Addiction Medicine (ASAM) in The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions (October 24, 2013).

(2) Qualified treatment programs for supervised work experience are:

(a) settings with a primary focus in licensed addiction counseling;

(b) Joint Commission on Accreditation of Healthcare Organizations (JCAHO), Commission on Accreditation of Rehabilitation Facilities (CARF), or Council on Accreditation (COA) approved settings;

(c) Indian Health Service (IHS)-approved settings;

(d) organized licensed addiction counseling settings within branches of the armed forces of veterans' administration hospitals;

(e) licensed mental health centers; and

(f) organized group practice setting (two or more licensed addiction counselors in a defined, conjoint practice). The work setting must have the capacity to provide multidisciplinary supervision.

(3) Qualified treatment programs must have a direct referral relationship for the provision of:

(a) detoxification services;

(b) medical services;

(c) laboratory services;

(d) psychiatric consultations; and

(e) psychological consultations.

(4) Qualified treatment programs must demonstrate the individualized treatment plans including:

(a) problem formulations;

(b) goals;

(c) measurable treatment objectives;

(d) progress notes; and

(e) regular reviews of plans at specified times by a designated treatment team.

 

History: 37-1-131, 37-35-103, 37-35-202, MCA; IMP, 37-1-131, 37-35-103, 37-35-202, MCA; NEW, 2016 MAR p. 1457, Eff. 8/20/16; TRANS from ARM 24.154.413, 2019 MAR p. 207, Eff. 2/23/19; AMD, 2019 MAR p. 2371, Eff. 12/28/19.